{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T14:57:52Z","timestamp":1789743472877,"version":"4.0.1"},"reference-count":13,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T00:00:00Z","timestamp":1615161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T00:00:00Z","timestamp":1615161600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann. Intensive Care"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      The classification of invasive pulmonary aspergillosis (IPA) issued by the European Organization for the Research and Treatment of Cancer\/Mycoses Study Group Education and Research Consortium (EORTC\/MSGERC) is used for immunocompromised patients. An alternative algorithm adapted to the intensive care unit (ICU) population has been proposed (AspICU), but this algorithm did not include microbial biomarkers such as the galactomannan antigen and the\n                      <jats:italic>Aspergillus<\/jats:italic>\n                      quantitative PCR. The objective of the present pilot study was to evaluate a new algorithm that includes fungal biomarkers (BM-AspICU) for the diagnosis of probable IPA in an ICU population.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>Data from 35 patients with pathology-proven IPA according to European Organization for the Research and Treatment of Cancer\/Mycosis Study Group (EORTC\/MSGERC)-2008 criteria were extracted from the French multicenter database of the Invasive Fungal Infections Surveillance Network (RESSIF). The patients were investigated according to the AspICU algorithm, and the BM-AspICU algorithm in analyzing the clinical, imaging, and biomarker data available in the records, without taking into account the pathology findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Eight patients had to be excluded because no imaging data were recorded in the database. Among the 27 proven IPAs with complete data, 16 would have been considered as putative IPA with the AspICU algorithm and 24 would have been considered as probable IPA using the new algorithm BM-AspICU. Seven out of the 8 patients with probable BM-AspICU IPA (and not classified with the AspICU algorithm) had no host factors and no\n                      <jats:italic>Aspergillus<\/jats:italic>\n                      -positive broncho-alveolar lavage fluid (BALF) culture. Three patients were non-classifiable with any of the two algorithms, because they did not have any microbial criteria during the course of the infection, and diagnosis of proven aspergillosis was done using autopsy samples.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Inclusion of biomarkers could be effective to identify probable IPA in the ICU population. A prospective study is needed to validate the routine application of the BM-AspICU algorithm in the ICU population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13613-021-00827-3","type":"journal-article","created":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T06:03:50Z","timestamp":1615183430000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["New clinical algorithm including fungal biomarkers to better diagnose probable invasive pulmonary aspergillosis in ICU"],"prefix":"10.1016","volume":"11","author":[{"name":"Collaborative RESSIF group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joffrey","family":"Hamam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Christophe","family":"Navellou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Pauline","family":"Bellanger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Bretagne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadrien","family":"Winiszewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emeline","family":"Scherer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gael","family":"Piton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5939-3409","authenticated-orcid":false,"given":"Laurence","family":"Millon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","published-online":{"date-parts":[[2021,3,8]]},"reference":[{"issue":"12","key":"827_CR1","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1086\/588660","volume":"46","author":"B De Pauw","year":"2008","unstructured":"De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group. Clin Infect Dis. 2008;46(12):1813\u201321.","journal-title":"Clin Infect Dis"},{"key":"827_CR2","first-page":"ciz1008","volume":"71","author":"JP Donnelly","year":"2019","unstructured":"Donnelly JP, Chen SC, Kauffman CA, et al. Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis. 2019;71:ciz1008.","journal-title":"Clin Infect Dis."},{"issue":"1","key":"827_CR3","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1164\/rccm.201111-1978OC","volume":"186","author":"SI Blot","year":"2012","unstructured":"Blot SI, Taccone FS, Van den Abeele A-M, et al. A clinical algorithm to diagnose invasive pulmonary aspergillosis in critically ill patients. Am J Respir Crit Care Med. 2012;186(1):56\u201364.","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"827_CR4","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/S2213-2600(18)30274-1","volume":"6","author":"AFAD Schauwvlieghe","year":"2018","unstructured":"Schauwvlieghe AFAD, Rijnders BJA, Philips N, et al. Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study. Lancet Respir Med. 2018;6(10):782\u201392.","journal-title":"Lancet Respir Med"},{"issue":"8","key":"827_CR5","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1007\/s00134-020-06091-6","volume":"46","author":"PE Verweij","year":"2020","unstructured":"Verweij PE, Rijnders BJA, Br\u00fcggemann RJM, et al. Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion. Intensive Care Med. 2020;46(8):1524\u201335.","journal-title":"Intensive Care Med"},{"key":"827_CR6","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1298","author":"PL White","year":"2020","unstructured":"White PL, Dhillon R, Cordey A, et al. A national strategy to diagnose COVID-19 associated invasive fungal disease in the ICU. Clin Infect Dis. 2020. https:\/\/doi.org\/10.1093\/cid\/ciaa1298.","journal-title":"Clin Infect Dis."},{"issue":"3","key":"827_CR7","doi-asserted-by":"publisher","first-page":"145","DOI":"10.5603\/AIT.2014.0027","volume":"46","author":"S Teering","year":"2014","unstructured":"Teering S, Verreth A, Peeters A, et al. Prognostic value of serum galactomannan in mixed ICU patients: a retrospective observational study. Anaesthesiol Intensive Ther. 2014;46(3):145\u201354.","journal-title":"Anaesthesiol Intensive Ther"},{"issue":"Suppl 1","key":"827_CR8","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","volume":"24","author":"AJ Ullmann","year":"2018","unstructured":"Ullmann AJ, Aguado JM, Arikan-Akdagli S, et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect. 2018;24(Suppl 1):e1-38.","journal-title":"Clin Microbiol Infect"},{"issue":"9","key":"827_CR9","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1513\/AnnalsATS.201811-766OC","volume":"16","author":"Q Haydour","year":"2019","unstructured":"Haydour Q, Hage CA, Carmona EM, et al. Diagnosis of fungal infections. A systematic review and meta-analysis supporting American Thoracic Society Practice Guideline. Ann Am Thorac Soc. 2019;16(9):1179\u201388.","journal-title":"Ann Am Thorac Soc."},{"issue":"6","key":"827_CR10","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1016\/S2213-2600(20)30237-X","volume":"8","author":"A Alanio","year":"2020","unstructured":"Alanio A, Delli\u00e8re S, Fodil S, et al. Prevalence of putative pulmonary aspergillosis in critically ill patients with COVID-19. Lancet Respir Med. 2020;8(6):e48\u20139.","journal-title":"Lancet Respir Med."},{"issue":"1","key":"827_CR11","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1164\/rccm.202004-1038LE","volume":"202","author":"ALE Van Arkel","year":"2020","unstructured":"Van Arkel ALE, Rijpstra TA, Belderbos HNA, van Wijngaarden P, Verweij PE, Bentvelsen RG. COVID-19 associated pulmonary Aspergillosis. Am J Respir Crit Care Med. 2020;202(1):132\u20135.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"827_CR12","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13613-020-00686-4","volume":"10","author":"L Rutsaert","year":"2020","unstructured":"Rutsaert L, Steinfort N, Van Hunsel T, Bomans P, Naesens R, Mertes H, Dits H, Van Regenmortel N. COVID-19-associated invasive pulmonary Aspergillosis. Ann Intensive Care. 2020;10(1):71.","journal-title":"Ann Intensive Care"},{"key":"827_CR13","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1086\/518852","volume":"45","author":"W Meersseman","year":"2007","unstructured":"Meersseman W, Lagrou K, Maertens J, Van Wijngaerden E. Invasive aspergillosis in the intensive care unit. Clin Infect Dis. 2007;45:205\u201316.","journal-title":"Clin Infect Dis"}],"container-title":["Annals of Intensive Care"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13613-021-00827-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13613-021-00827-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13613-021-00827-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T06:39:13Z","timestamp":1767767953000},"score":1,"resource":{"primary":{"URL":"https:\/\/annalsofintensivecare.springeropen.com\/articles\/10.1186\/s13613-021-00827-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,8]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["827"],"URL":"https:\/\/doi.org\/10.1186\/s13613-021-00827-3","relation":{},"ISSN":["2110-5820"],"issn-type":[{"value":"2110-5820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,8]]},"assertion":[{"value":"7 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The RESSIF network was approved by the Institut Pasteur institutional review board (IRB #2009-34). Approval of the \"Commission Nationale de l'Informatique et des Libert\u00e9s\" was obtained, ensuring that patient\u2019s data were kept and used according to French regulation. The BM-AspICU substudy was approved by the coordinating committee of RESSIF\u00a0in April 2019.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have disclosed that they do not have any potential conflicts of interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"41"}}